

**UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF ILLINOIS**

**IN RE: YASMIN AND YAZ
(DROSPIRENONE) MARKETING, SALES
PRACTICES AND PRODUCTS LIABILITY
LITIGATION**

)
)
)
)
)

**3:09-md-02100-DRH-
PMF
MDL No. 2100**

This Document Relates to:

ALL CASES

CASE MANAGEMENT ORDER NO. 33

(Effect of Name Change By Bayer Schering Pharma AG)

Effective July 1, 2011, the entity known as Bayer Schering Pharma AG (Former Name) will be named Bayer Pharma AG (New Name). See Notice of Name Change (Master Docket 1810). To avoid any confusion as to the effectiveness or applicability of stipulations, orders, and other pleadings or documents that may arise as a result of this name change,

IT IS HEREBY ORDERED that any and all stipulations, orders, other pleadings or documents filed in or related to this MDL proceeding that refer to Bayer Schering Pharma AG (or any abbreviation thereof), *i.e.*, the Former Name, are hereby reformed to correctly reflect the new name of defendant, Bayer Pharma AG, and are valid and enforceable as if the new name of defendant was set forth therein.

Plaintiffs who have named Bayer Schering Pharma AG as a defendant are not required to amend their complaints to reflect the entity's New Name. If a plaintiff files an amended complaint for the sole purpose of incorporating the New Name, the defendants that have already filed answers are not required to file answers to that amended complaint.

In all future filings, documents, or proceedings related to this MDL, the parties are encouraged to refer to this entity as Bayer Pharma AG. However, absent an express statement to the contrary, any future reference to Bayer Schering Pharma AG will be deemed a reference to Bayer Pharma AG.

SO ORDERED.

 Digitally signed by
David R. Herndon
Date: 2011.07.05
10:48:00 -05'00'

**Chief Judge
United States District**

Date: July 5, 2011